![[höher]](/style/images/multi_up.png)
Eine Ebene höherGruppiert nach:
Dokumententyp
| Veröffentlichungsdatum
Springe zu: Zeitschriftenartikel
Anzahl der Publikationen: 2
Zeitschriftenartikel
Dowsett, Mitch; Ellis, Matthew J. 
ORCID: https://orcid.org/0000-0002-8467-8534; Dixon, J. Michael; Gluz, Oleg; Robertson, John; Kates, Ronald; Suman, Vera J.; Turnbull, Arran K.; Nitz, Ulrike; Christgen, Matthias; Kreipe, Hans; Kuemmel, Sherko; Bliss, Judith M.; Barry, Peter; Johnston, Stephen R.; Jacobs, Samuel A.; Ma, Cynthia X.; Smith, Ian E. und Harbeck, Nadia ORCID: https://orcid.org/0000-0002-9744-7372
(2020):
Evidence-based guidelines for managing patients with primary ER+ HER2- breast cancer deferred from surgery due to the COVID-19 pandemic.
In: Npj Breast Cancer, Bd. 6, Nr. 1, 21: S. 1-10
[PDF, 1MB]
ORCID: https://orcid.org/0000-0002-8467-8534; Dixon, J. Michael; Gluz, Oleg; Robertson, John; Kates, Ronald; Suman, Vera J.; Turnbull, Arran K.; Nitz, Ulrike; Christgen, Matthias; Kreipe, Hans; Kuemmel, Sherko; Bliss, Judith M.; Barry, Peter; Johnston, Stephen R.; Jacobs, Samuel A.; Ma, Cynthia X.; Smith, Ian E. und Harbeck, Nadia ORCID: https://orcid.org/0000-0002-9744-7372
(2020):
Evidence-based guidelines for managing patients with primary ER+ HER2- breast cancer deferred from surgery due to the COVID-19 pandemic.
In: Npj Breast Cancer, Bd. 6, Nr. 1, 21: S. 1-10
[PDF, 1MB]
Robertson, John F. R.; Evans, Abigail; Henschen, Stephan; Kirwan, Cliona C.; Jahan, Ali; Kenny, Laura M.; Dixon, J. Michael; Schmid, Peter; Kothari, Ashutosh; Mohamed, Omar; Fasching, Peter A.; Cheung, Kwok-Leung; Würstlein, Rachel; Carroll, Danielle; Klinowska, Teresa; Lindemann, Justin P. O.; MacDonald, Alexander; Mather, Richard; Maudsley, Rhiannon; Moschetta, Michele; Nikolaou, Myria; Roudier, Martine P.; Sarvotham, Tinnu; Schiavon, Gaia; Zhou, Diansong; Zhou, Li und Harbeck, Nadia
(2020):
A Randomized, Open-label, Presurgical, Window-of-Opportunity Study Comparing the Pharmacodynamic Effects of the Novel Oral SERD AZD9496 with Fulvestrant in Patients with Newly Diagnosed ER+ HER2(-) Primary Breast Cancer.
In: Clinical Cancer Research, Bd. 26, Nr. 16: S. 4242-4249